Revance Therapeutics reported $-2631000 in Equity Capital and Reserves for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Equity Capital And Reserves Change
Aerie Pharmaceuticals AERI:US $ -141.13M 15.42M
ALKERMES ALKS:US $ 1082.32M 6.93M
Bristol Myers Squibb BMY:US $ 32600M 1020M
Cara Therapeutics CARA:US $ 204.42M 307K
Coherus Biosciences CHRS:US $ -22.63M 35.19M
Eli Lilly And LLY:US $ 8544.7M 786.1M
Endo International Ordinary Shares ENDP:US $ -3198.07M 1887.07M
Horizon Pharma HZNP:US $ 4945.53M 127.7M
JAZZ PHA JAZZ:US $ 3200.78M 407.71M
Neurocrine Biosciences NBIX:US $ 1423.4M 32.3M
Pacira Pharmaceuticals PCRX:US $ 756.64M 47.06M
Procter & Gamble PG:US $ 46854M 1376M
Revance Therapeutics RVNC:US $ -2.63M 28.17M
Supernus Pharmaceuticals SUPN:US $ 841.43M 12.99M
Teva Pharmaceutical Industries TEVA:US $ 9037M 307M